The landscape of diabetes treatment is undergoing a significant shift, driven by the increasing integration of technology into clinical care. The ATTD 2026 Congress, a leading international forum on advanced diabetes technologies, highlights a growing trend: innovation is moving beyond a supplemental role to become a core component of treatment plans.
Companies like Dexcom are at the forefront of this change, pioneering a new approach to diabetes management. As a leader in continuous glucose monitoring (CGM), Dexcom is focused on transforming data into actionable insights for individuals, informed by both scientific evidence and the experiences of patients and healthcare professionals. This approach points toward a future where personalized care is central to diabetes treatment.
This evolution is supported by tools capable of providing continuous and reliable glucose level information, enabling a transition from reactive to proactive management. Real-time data access facilitates more precise clinical decisions and allows for treatment adjustments tailored to each person’s needs. Effective diabetes management is crucial for preventing long-term health complications, making advancements in this field particularly important.
The integration of technology isn’t simply about adding devices to standard practice; it’s about recognizing technology’s potential to fundamentally change the patient-disease relationship, enhance a clinician’s ability to anticipate issues, and reshape how healthcare systems deliver care. “We are moving from a reactive approach to a continuous and proactive model that allows us to anticipate problems and improve daily diabetes management,” explains Raquel García Gordon, General Manager of Dexcom Spain. “Technology has ceased to be a complement to treatment and has become the key to overcoming outdated options. We cannot address the challenges of 2026 with tools from the past; innovation must be constant to ensure the efficiency of the system.”
Technology at the Heart of Treatment
Continuous glucose monitoring (CGM) is solidifying its position as a transformative tool in this new environment. Its value lies not only in measurement, but in converting data into personalized clinical decisions. This can lead to improvements in metrics like time in range, reduced daily burden, and increased autonomy for people living with diabetes. When this information is clear, understandable, and actionable, it becomes a powerful lever for refining treatment and sustaining lifestyle changes.
The application of this technology is similarly gaining traction in type 2 diabetes treated with basal insulin. Dr. Fernando Gómez Peralta, Coordinator of the Diabetes Area of the Spanish Society of Endocrinology and Nutrition (SEEN) and Head of the Endocrinology and Nutrition Unit at the General Hospital of Segovia, emphasizes that the available scientific evidence is strong. “Trials have shown significant improvements in glycemic control and reductions in hypoglycemia.” He also notes that seeing data in real-time makes CGM “a very powerful tool for self-management,” even in relation to rapid lifestyle adjustments.
This is particularly relevant because it places the patient in a more active role. The ability to observe how diet, exercise, or medication adherence influences glucose levels fosters a more direct understanding of the disease and can improve engagement in daily management.
Experts also point to its potential in a broader context of metabolic health and cardiovascular prevention. Continuous access to data allows for earlier detection of abnormalities and intervention before more serious complications arise.
Continuous glucose monitoring allows for the transformation of data into personalized clinical decisions, improving diabetes management and reducing the patient’s daily burden.
Equity, Evidence, and Real-World Application in Healthcare
Technological advancements coincide with growing public demand for a more proactive and personalized healthcare system. A study on social perception of artificial intelligence and technology applied to diabetes in Spain, conducted by the UdG-Dexcom Chair alongside Dexcom and the Spanish Diabetes Federation, reveals strong public support for a more preventative, personalized, and technology-supported healthcare system. Over 90% of the population believes the public healthcare system should incorporate technological tools to promote healthy habits, and 87% believe access should depend on clinical need, not place of residence. Raquel García Gordon notes that these results demonstrate that healthcare innovation should not be limited by regional disparities. “Spanish society not only values technology in health, but demands equitable access to it,” she states.
From Dexcom’s perspective, this scenario requires going beyond technological development. “Innovation only generates value when it is supported by clinical evidence, accompanied by training, and can be integrated seamlessly into clinical practice.” This combination of technology, education, and real-world application will be crucial to ensure that the shift in the care model doesn’t remain an aspiration, but reaches the clinic and the daily lives of patients.
However, transforming the care model requires more than just having excellent devices. It also requires data to be understandable, actionable, and useful in clinical settings. Dr. Gómez Peralta stresses that “the challenge lies in automating analyses and integrating this information directly into electronic health record systems so that it can be translated into applicable and sustainable decisions within the healthcare system.”
For Dexcom, the future of diabetes care lies in integrated and personalized care based on evidence, where continuous glucose monitoring acts as a key lever for more preventative care aligned with the real lives of individuals, always with equitable access to innovation.
